Luc Dochez

Chairman

Mr Luc Dochez is Chairman of the Board of Directors and has been a Venture Partner at DROIA Ventures since December 2018. He was Chief Executive Officer of Tusk Therapeutics from May 2015 until its acquisition by Roche in September 2018. He joined Tusk from Prosensa Holding N.V. where he served as Chief Business Officer and Senior Vice President of Business Development for a period of seven years until its acquisition by BioMarin Pharmaceutical Inc. Earlier in his career, he served as Vice President of Business Development at TiGenix, Director Business Development at Methexis Genomics, and as consultant at Arthur D. Little.

Mr Dochez holds a Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an MBA from Vlerick Management School (Belgium).